AstraZeneca: Neoplasms trials

The registry lists 127 Neoplasms studies with AstraZeneca as lead sponsor. 8 are open to participants now and 47 have results posted.

Phase 1 81Phase 2 27Phase 3 13Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host DiseaseCompletedNCT00806728Phase 1
• Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid TumorsTerminatedNCT00796055Phase 1
• DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)CompletedNCT00748891Phase 1
• Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918TerminatedNCT00733031Phase 1
• A Study of Tor Kinase Inhibitor in Advanced TumorsCompletedNCT00731263Phase 1
• An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing ChemotherapyTerminatedNCT00721981
• Study of AZD8931 in Patients With Advanced Solid MalignanciesCompletedNCT00637039Phase 1
• Open-Label Extension of Other SZ1839 (Iressa) TrialsCompletedNCT00635973Phase 3
• A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult PatientsCompletedNCT00613652Phase 1
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedNCT00600496Phase 1
• Open Label, Dose Escalation Phase I Study of AZD2281CompletedNCT00572364Phase 1
• Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourCompletedNCT00503204Phase 1
• Phase I Study in Patients With Solid TumoursCompletedNCT00496028Phase 1
• Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
• Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and IrinotecanTerminatedNCT00473616Phase 1
• AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid MalignanciesActive, not recruitingNCT00463814Phase 1
• Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic MalignanciesTerminatedNCT00460460Phase 1
• AZD8330 First Time in Man in Patients With Advanced MalignanciesCompletedNCT00454090Phase 1
• Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid TumorsCompletedNCT00389389Phase 1
• AZD1152 in Patients With Advanced Solid MalignanciesCompletedNCT00338182Phase 1
• Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal CancerCompletedNCT00284817Phase 1/2
• Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid TumorsCompletedNCT00263783Phase 1
• Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or MetastaticCompletedNCT00127829Phase 1
• Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaTerminatedNCT00105313Phase 1
• AZD5438 in Patients With Advanced Solid MalignanciesCompletedNCT00088790Phase 1
• Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.TerminatedNCT00065117Phase 2
• Iressa Expanded Access Program (EAP)CompletedNCT00034879Phase 3